Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Superficial Bladder Carcinoma

Known as: Superficial Bladder Cancer, Superficial Urinary Bladder Cancer, Superficial Urinary Bladder Carcinoma 
A term used by urologists to describe an infiltrating carcinoma of the bladder that has not invaded into the muscularis propria of the bladder wall… Expand
National Institutes of Health

Related topics

Related topics

8 relations
Epithelial CellsEpitheliumHematuriaMalignant Epithelial Cell
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
OBJECTIVES To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
OBJECTIVES To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on… Expand
  • table I
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
PURPOSE We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-Guerin (BCG) with mitomycin C on… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
PURPOSE We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection… Expand
Is this relevant?
Review
2000
Review
2000
Multivariate analysis of the prognostic factors of primary superficial bladder cancer.
PURPOSE We evaluate the prognostic factors of recurrence, progression and disease specific mortality in patients with primary… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.
PURPOSE We identified risk groups in primary superficial bladder cancer according to progression, mortality and recurrence rates… Expand
Is this relevant?
Review
1997
Review
1997
The treated natural history of high risk superficial bladder cancer: 15-year outcome.
PURPOSE The long-term outcome of patients with high risk superficial bladder cancer is unknown. We report the results of 15 years… Expand
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group.
A double-blind trial was conducted in 138 patients with superficial transitional cell carcinoma of the bladder following… Expand
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in the prophylaxis and treatment of… Expand
Is this relevant?
Highly Cited
1991
Highly Cited
1991
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
BACKGROUND In carcinoma of the bladder, both intravesical chemotherapy and immunotherapy can induce tumor regression and reduce… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE